20031120
 Merck Cancels Its Development Of Diabetes Drug   By Landers, Peter, The Wall Street Journal,  Nov 21, 2003  Merck said it identified a rare malignant tumor in mice that had been given the drug. It said the relevance of that discovery in humans isn't known, but the company has told doctors to stop testing the drug in humans. The drug, known by the development number MK-767, had been in Phase III trials, the final step before seeking approval from the Food and Drug Administration to sell the drug. Merck said the trials included 2,200 people, of whom 1,400 were taking MK-767 and the rest a placebo.   
